osteosarcoma
Study Finds 28 Percent of Osteosarcoma Patients Have High-Penetrance Germline Mutations
The authors of the study noted that these genetic findings could guide better clinical decisions for patients and improve outcomes.
NCI Pediatric MATCH Trial Interim Data Shows 24 Percent of Patients Eligible for Targeted Therapy
Premium
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.
Subset of Bone Cancers Have Mutations Affecting IGF Signaling, Suggesting Possible Treatment
Researchers led by the Wellcome Trust Sanger Institute also reported that combined chromothripsis and amplification might be a driving mechanism of osteosarcoma.
The collaborators hope initial research in canines can be a proving ground for synthetic viruses designed to kill particular tumors, perhaps even in humans.
The study identified five SNPs significantly associated with five-year progression-free survival and defined risk groups with widely different risks of disease recurrence.